Pressor response to microinjection of orexin/hypocretin into rostral ventrolateral medulla of awake rats.
Orexin A (or hypocretin 1)-immunoreactive neurons in the rat lateral hypothalamus project to several areas of the medulla oblongata that are closely associated with cardiovascular regulation. The present study was undertaken to further strengthen the hypothesis that orexin A accelerates cardiovascular response by activating sympathoexcitatory neurons in the rat rostral ventrolateral medulla (RVLM). First, immunohistochemical studies revealed the presence of orexin A-immunoreactive fibers in the RVLM. Double labeling the sections with orexin A- and tyrosine hydroxylase (TH)-antisera further showed that orexin A-immunoreactive fibers are in close proximity with TH-immunoreactive neurons, some of which may be barosensitive, bulbospinal neurons in the RVLM. Second, microinjection of orexin A (6.35, 12.7 and 38.1 microM) into the RVLM, which was verified later by histological examination, caused a significant increase of mean arterial pressure (MAP) and a moderate increase of heart rate (HR) in awake rats. L-glutamate (33.3 mM) injected into the same sites, caused a larger increase in MAP, but a decrease in HR; whereas, saline injection was without significant effect. Results from this study suggest that orexin A, which may be released from the nerve fibers originating from the neurons in the lateral hypothalamus, acting on RVLM neurons in the medulla, increases sympathetic outflow targeted to the heart and blood vessels in awake animals.
Machado
Benedito H
BH
Department of Physiology, School of Medicine Ribeirão Preto, University of São Paulo, 14049-900, Ribeirão Preto, SP, Brazil.
Bonagamba
Leni G H
LG
Dun
Siok L
SL
Kwok
Ernest H
EH
Dun
Nae J
NJ
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002319:Cardiovascular System; D002352:Carrier Proteins / Q000494:pharmacology*; D003243:Consciousness / Q000502:physiology; D018698:Glutamic Acid / Q000494:pharmacology; D006339:Heart Rate / Q000187:drug effects; D007276:Injections, Intraventricular / Q000379:methods; D047908:Intracellular Signaling Peptides and Proteins; D008297:Male; D008526:Medulla Oblongata / Q000033:anatomy & histology / Q000187:drug effects* / Q000502:physiology; D008845:Microinjections / Q000379:methods; D009474:Neurons / Q000166:cytology / Q000187:drug effects / Q000502:physiology; D009479:Neuropeptides / Q000494:pharmacology*; D000068797:Orexins; D011311:Pressoreceptors / Q000187:drug effects* / Q000502:physiology; D051381:Rats; D017208:Rats, Wistar; D014446:Tyrosine 3-Monooxygenase / Q000502:physiology
D002352:Carrier Proteins; D047908:Intracellular Signaling Peptides and Proteins; D009479:Neuropeptides; D000068797:Orexins; D018698:Glutamic Acid; D014446:Tyrosine 3-Monooxygenase